S&P Futures
4,076.25 -8.50 (-0.21%) Dow Futures
32,540.00 -41.00 (-0.13%) Nasdaq Futures
12,513.75 -46.50 (-0.37%) Russell 2000 Futures
1,832.70 -4.50 (-0.24%) Crude Oil
113.32 +0.92 (+0.82%) Gold
1,807.10 -11.80 (-0.65%)
Genenta Science S.p.A. (GNTA)
Chart Events
Performance Outlook
| Previous Close | 5.86 |
| Open | 5.96 |
| Bid | 0.00 x 1100 |
| Ask | 9.77 x 2900 |
| Day's Range | 5.96 - 6.39 |
| 52 Week Range | 5.11 - 13.13 |
| Volume | |
| Avg. Volume | 9,060 |
| Market Cap | 114.066M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.50 |
- GlobeNewswire
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May and June. Details of the presentations are as follows: American Society of Cell and Gene Therapy (ASGCT) 25th Annual Meeting, May 16-19, Washington and virtualTitle: Autologous Cell & Gene Therapy for the
- AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive MeasuresBusiness Wire
- Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual MeetingGlobeNewswire
- GlobeNewswire
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
Extensive experience in business development with AstraZeneca and GSKMILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Tim Obara, a highly experienced commercial healthcare executive, as Vice President Business Development. Tim has significant experience across a broad range of therapeutic ar
- GlobeNewswire
Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report can be accessed on the Company's investor relations website at https://ir.genen
